Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Unicycive Therapeutics (UNCY – Research Report) today and set a price ...

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a price target of ...

LOS ALTOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive ...

The FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease ...

Unicycive, which is seeking an FDA green light for oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis, Monday said the agency set a target ...

On Friday, Unicycive Therapeutics Inc (UNCY) stock saw a modest uptick, ending the day at $0.59 which represents a slight increase of $0.02 or 3.51% from the prior close of $0.57. The stock opened at ...

UNCY Stock Performance and Moving Averages. In recent trading, Unicycive Therapeutics Inc (UNCY) stock price has shown some volatility, fluctuating 6.50% over the last five trades ...

Unicycive has entered into a long term manufacturing contract with Shilpa Medicare for the supply of the product at commercial scale once approved by the USFDA. With Unicycive's NDA now under review, ...

FDA sets PDUFA Action Date of June 28, 2025 ...

Unicycive Therapeutics (UNCY) announced that multiple presentations were delivered at the American Society of Nephrology Kidney Week 2024 that highlighted the extensive development progress for ...

LOS ALTOS, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the ...

Detailed price information for Unicycive Therapeutics Inc (UNCY-Q) from The Globe and Mail including charting and trades.